Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 21, 2026, MAIA Biotechnology, Inc. (the "Company") (NYSE American: MAIA) held its 2026 Annual Meeting of stockholders (the "Annual Meeting"). For more information on the proposals, which are described below, please refer to the Company's definitive proxy statement, dated April 7, 2026, as filed by the Company with the Securities and Exchange Commission on April 7, 2026.

As of the record date of March 23, 2026, there were 60,671,491 shares of the Company's common stock issued and outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, there were present, in person or by proxy, shareholders holding an aggregate of 37,547,754 shares of common stock, representing approximately 61.88% of the shares of common stock issued and outstanding and entitled to vote at the Annual Meeting; therefore a quorum was present. The following matters were submitted to a vote of stockholders at the Annual Meeting:

1. Election of Class I Directors

Stockholders re-elected both of the Company's Class I nominees for director for three-year terms expiring on the annual meeting of stockholders to be held in 2029 or until their successors are duly elected and qualified. Each of the nominees is currently serving as a member of our board of directors. The voting results were as follows:

2. Ratification of Auditors

Stockholders ratified the appointment of Grant Thornton LLP to serve as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows: